Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut - Huber, Henriette; Tausch, Eugen; Schneider, Christof; Edenhofer, Simone; Tresckow, Julia von; Robrecht, Sandra; Giza, Adam; Zhang, Can; Fürstenau, Moritz; Dreger, Peter; Ritgen, Matthias; Illmer, Thomas; et al. (Blood, 2023)